Yüklüyor......
CDK4/6 inhibitor palbociclib overcomes acquired resistance to third‐generation EGFR inhibitor osimertinib in non‐small cell lung cancer (NSCLC)
BACKGROUND: The third‐generation EGFR‐TKI, represented by osimertinib, has been widely used in clinical practice; however, resistance eventually emerges. At present, it remains unclear whether an abnormal cell cycle is involved in acquired resistance, and whether the combination of palbociclib (CDK4...
Kaydedildi:
| Yayımlandı: | Thorac Cancer |
|---|---|
| Asıl Yazarlar: | , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley & Sons Australia, Ltd
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7471056/ https://ncbi.nlm.nih.gov/pubmed/32677256 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13521 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|